A drugmaker is pulling a lot of thyroid tablets from the market nationwide because testing confirmed the pills may contain more hormone than the label says, an unusual reversal of the more familiar pattern in which recalled thyroid medicine turns out to be too weak.
Vitruvias Therapeutics, based in Auburn, Alabama, is recalling one lot of Thyroid Tablets, USP 30 mg to the consumer level. The affected lot is number 504950, carrying national drug code 69680-166-00 and an expiration date of September 30, 2026. The company issued the announcement on August 21, 2026, and the FDA published it three days later. The agency posts company recall announcements as a public service without endorsing the product or the firm.
The recall is voluntary and company-initiated, conducted with the FDA's knowledge. Vitruvius says it has received no reports of adverse events known to be related to it.
The number that matters to households is small but not trivial. Of 3,655 units released, 1,955 were sold and distributed nationwide to the company's direct accounts between January 31 and September 30 of last year. Because the expiration date has not yet passed, bottles from this lot can still be sitting in medicine cabinets.
Too Much Hormone Behaves Differently Than Too Little
This is the part worth understanding, because it changes the timeline for symptoms.
Thyroid USP is a natural preparation made from porcine thyroid glands, containing both levothyroxine and liothyronine, and it is prescribed for hypothyroidism. When such a product is subpotent, patients typically drift back into hypothyroid symptoms over weeks, which is slow and easy to mistake for stress or aging.
A superpotent product works in the other direction. Excess thyroid hormone can produce hyperthyroidism, and the company's risk statement lists weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances among the possible effects.
Several of those are cardiac. That is why this recall reads differently from a routine potency deviation, and why the company identified specific groups as facing greater risk.
The Groups Facing the Greatest Risk
Vitruvias identified older adults, pregnant women, and infants as the populations at greater risk from superpotent thyroid product, particularly over extended periods.
For older adults, the concern is the heart. Excess thyroid hormone levels in this group have been associated with adverse outcomes, particularly cardiac ones. An older patient with existing heart disease who develops palpitations or chest discomfort has a specific reason to be evaluated promptly rather than waiting for a routine appointment.
In pregnancy, overtreatment of hypothyroidism is associated with a higher rate of maternal and fetal complications, including premature delivery and low birth weight. A pregnant patient taking thyroid medication should not stop it, and should not adjust the dose independently, but should contact the prescriber to confirm which product and lot she is taking.
In infants, overtreatment may negatively affect growth and development.
Everyone else taking the affected lot faces a lower but real risk, and the appropriate response is the same: check. People with existing heart rhythm problems, coronary disease, or osteoporosis have added reason to raise the recall with their prescriber, since sustained overtreatment with thyroid hormone is recognized as a concern for both cardiac and bone health.
The Check Takes Under a Minute
Look at the prescription bottle or the pharmacy label for the product name Thyroid Tablets, USP 30 mg, the distributor Vitruvias Therapeutics, and the lot number 504950. If the lot number is not printed on the label, the dispensing pharmacy can look it up from the fill record.
If the lot matches, do not stop taking the medication on your own. The company is explicit on this point: patients currently taking product from the recalled lot should not discontinue use without contacting a healthcare provider for guidance or a replacement prescription. Abruptly stopping thyroid hormone creates its own problems, and untreated hypothyroidism is not a safer state than a potency question.
Call the prescriber or the pharmacy, describe the recall, and request a replacement supply from an unaffected lot. Most pharmacies replace recalled prescription medication at no additional cost. Patients concerned about cost differences between manufacturers can ask the pharmacist about equivalents, and those without insurance can ask about generic pricing programs and manufacturer assistance.
Consumers with questions can reach Vitruvias Therapeutics by phone at (256) 239-9373, Monday through Friday from 9 a.m. to 5 p.m. Central, or by email at the address listed in the company announcement.
Anyone who has experienced problems that may relate to the product should tell a clinician and can report the event through the FDA's MedWatch adverse event reporting program.
Symptoms That Warrant a Call and Those That Warrant Urgency
Mild symptoms that build gradually, such as feeling unusually warm, jittery, or tired, unexplained weight loss, or trouble sleeping, are reasons to contact a clinician and ask whether thyroid function should be rechecked. A thyroid-stimulating hormone test is the usual next step, and clinicians typically interpret it in the context of when any dose or product change occurred. Because thyroid hormone clears the body slowly, clinicians often wait several weeks after a change before rechecking, so a normal result taken too early does not always settle the question.
Chest pain, a racing or irregular heartbeat, fainting, severe shortness of breath, or sudden confusion are different. Those require urgent medical evaluation rather than a message left with an office.
This article is general information and is not a diagnosis. No one should start, stop, or change a thyroid prescription without speaking to a qualified clinician.
MedicalDaily reported last month on a separate nationwide recall of subpotent levothyroxine tablets, a different company and a different problem. Readers who checked their bottles then should check again, because a lot number that cleared one recall says nothing about another. The two products are not interchangeable either, since natural desiccated thyroid contains both levothyroxine and liothyronine while standard levothyroxine contains only one of them.
The FDA may classify this recall in the coming weeks, a step that assigns a formal risk category and appears in the agency's weekly enforcement reports. MedicalDaily will report the classification and any expansion of the recall to additional lots.
Key Questions Answered
What was recalled? One lot of Thyroid Tablets, USP 30 mg distributed by Vitruvias Therapeutics, lot number 504950, national drug code 69680-166-00, expiring September 30, 2026.
Why was it recalled? Testing confirmed the product's potential to be superpotent, meaning it may contain more thyroid hormone than the label indicates.
Should patients stop taking it? No. The company advises patients not to discontinue use without contacting a healthcare provider for guidance or a replacement prescription.
Who faces the greatest risk? The company identified older adults, pregnant women, and infants as being at greater risk, especially with prolonged exposure.
What symptoms could excess thyroid hormone cause? Weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances.
Have any injuries been reported? The company states it has received no reports of adverse events known to be related to this recall.
How do patients get a replacement? Contact the prescribing clinician or the dispensing pharmacy. Most pharmacies replace recalled prescription medication at no additional cost.
